The use of fulvestrant, an analogue of E2 that down-regulates and degrades ER-α without agonism (SERD), has been shown to suppress E2-induced proliferation of ER-α positive gastric cancer cells, and synergize with paclitaxel. This evidence concerns the gene ESR1 and gastric cancer.